{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:32:48Z","timestamp":1793392368011,"version":"4.5.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1016\/j.pharmthera.2009.10.010","type":"journal-article","created":{"date-parts":[[2009,11,18]],"date-time":"2009-11-18T14:46:50Z","timestamp":1258555610000},"page":"169-179","source":"Crossref","is-referenced-by-count":344,"title":["Metabolic side effects of antipsychotic drug treatment \u2013 pharmacological mechanisms"],"prefix":"10.1016","volume":"125","author":[{"given":"Gavin P","family":"Reynolds","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shona L.","family":"Kirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/oby.2006.6","article-title":"Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents","volume":"14","author":"Albaugh","year":"2006","journal-title":"Obesity"},{"issue":"9491","key":"10.1016\/j.pharmthera.2009.10.010_bib2","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(05)67402-8","article-title":"The metabolic syndrome\u2014a new worldwide definition","volume":"366","author":"Alberti","year":"2005","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.pharmthera.2009.10.010_bib3","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.10.010_bib4","doi-asserted-by":"crossref","first-page":"267","DOI":"10.4088\/JCP.v65n0219","article-title":"Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"65","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.10.010_bib5","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.4088\/JCP.v65n1007","article-title":"Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients","volume":"65","author":"Arranz","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0893-133X(01)00237-8","article-title":"Inverse agonist properties of antipsychotic agents at cloned, human (h) serotonin (5-HT)(1B) and h5-HT(1D) receptors","volume":"25","author":"Audinot","year":"2001","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.10.010_bib7","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1055\/s-2007-979502","article-title":"Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation","volume":"30","author":"Baptista","year":"1997","journal-title":"Pharmacopsychiatry"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.10.010_bib8","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00023210-200822060-00003","article-title":"Pharmacological management of atypical antipsychotic-induced weight gain","volume":"22","author":"Baptista","year":"2008","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib9","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/sj.npp.1301136","article-title":"Blockade of 5-HT2a receptors reduces haloperidol-induced attenuation of reward","volume":"32","author":"Benaliouad","year":"2007","journal-title":"Neuropsychopharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.10.010_bib10","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1177\/0269881105056641","article-title":"Actions of antipsychotic drugs on pancreatic \u03b2-cell function: contrasting effects of clozapine and haloperidol","volume":"19","author":"Best","year":"2005","journal-title":"J Psychopharmacol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.10.010_bib11","first-page":"BR47","article-title":"Pilot study of the G-protein beta3 subunit gene (C825T) polymorphism and clinical response to olanzapine or olanzapine-related weight gain in persons with schizophrenia","volume":"12","author":"Bishop","year":"2006","journal-title":"Med Sci Monit"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib12","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1080\/140174301750305045","article-title":"Heart and soul: stress and the metabolic syndrome","volume":"35","author":"Bjorntorp","year":"2001","journal-title":"Scand Cardiovasc J"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.2042-7158.1975.tb09374.x","article-title":"The effect of 5-hydroxytryptophan on food intake and on the anorexic action of amphetamine and fenfluramine","volume":"27","author":"Blundell","year":"1975","journal-title":"J Pharm Pharmacol"},{"issue":"4\u20135","key":"10.1016\/j.pharmthera.2009.10.010_bib14","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0028-3908(97)00049-X","article-title":"RS-102221: a novel high affinity and selective, 5-HT2C receptor antagonist","volume":"36","author":"Bonhaus","year":"1997","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib15","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00213-008-1207-7","article-title":"Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study","volume":"200","author":"Casey","year":"2008","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.10.010_bib16","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.2174\/138945006779025400","article-title":"Susceptibility genes for the side effect of antipsychotics on body weight and obesity","volume":"7","author":"Chagnon","year":"2006","journal-title":"Curr Drug Targets"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.10.010_bib17","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/ajmg.b.30554","article-title":"Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine","volume":"144B","author":"Chagnon","year":"2007","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.10.010_bib18","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/sj.mp.4001537","article-title":"A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational families of eastern Quebec affected by psychoses","volume":"9","author":"Chagnon","year":"2004","journal-title":"Mol Psychiatry"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.10.010_bib19","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1097\/JCP.0b013e31814fb9a3","article-title":"Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients","volume":"27","author":"Chen","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib20","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1007\/s002130000504","article-title":"Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist and d-fenfluramine on feeding patterns in the rat","volume":"152","author":"Clifton","year":"2000","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.10.010_bib21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1037\/0735-7044.105.2.272","article-title":"Effects of dopamine D1 and dopamine D2 antagonists on the free feeding and drinking patterns of rats","volume":"105","author":"Clifton","year":"1991","journal-title":"Behav Neurosci"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00213-005-2224-4","article-title":"A parametric analysis of olanzapine-induced weight gain in female rats","volume":"181","author":"Cooper","year":"2005","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.10.010_bib23","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/FBP.0b013e3282f62c66","article-title":"Comparative effects of olanzapine and ziprasidone on hypophagia induced by enhanced histamine neurotransmission in the rat","volume":"19","author":"Davoodi","year":"2008","journal-title":"Behav Pharmacol"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.schres.2005.12.855","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication","volume":"83","author":"De Hert","year":"2006","journal-title":"Schizophr Res"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2009.10.010_bib25","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.schres.2007.10.003","article-title":"Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels","volume":"98","author":"de Leon","year":"2008","journal-title":"Schizophr Res"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib26","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S0149-7634(99)00083-4","article-title":"Effects of selected serotonin 5-HT(1) and 5-HT(2) receptor agonists on feeding behavior: possible mechanisms of action","volume":"24","author":"De Vry","year":"2000","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.10.010_bib27","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1089\/thy.2007.0018","article-title":"Appetite regulation: an overview","volume":"17","author":"Dhillo","year":"2007","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.10.010_bib28","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1111\/j.1600-0447.2005.00637.x","article-title":"Obesity among individuals with serious mental illness","volume":"113","author":"Dickerson","year":"2006","journal-title":"Acta Psychiatr Scand"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2009.10.010_bib29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00431709","article-title":"Low doses of the putative serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) elicit feeding in the rat","volume":"86","author":"Dourish","year":"1985","journal-title":"Psychopharmacology"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2009.10.010_bib30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ejphar.2008.04.039","article-title":"Actions of novel agonists, antagonists and antipsychotic agents at recombinant rat 5-HT6 receptors: a comparative study of coupling to G alpha s","volume":"588","author":"Dupuis","year":"2008","journal-title":"Eur J Pharmacol"},{"issue":"5900","key":"10.1016\/j.pharmthera.2009.10.010_bib31","first-page":"168","volume":"1","author":"Editorial: drugs causing weight gain","year":"1974","journal-title":"Br Med J"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2009.10.010_bib32","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.schres.2007.09.030","article-title":"Metabolic syndrome and insulin resistance in schizophrenia patients receiving antipsychotics genotyped for the methylenetetrahydrofolate reductase (MTHFR) 677C\/T and 1298A\/C variants","volume":"98","author":"Ellingrod","year":"2008","journal-title":"Schizophr Res"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00041444-200203000-00008","article-title":"CYP2D6 polymorphisms and atypical antipsychotic weight gain","volume":"12","author":"Ellingrod","year":"2002","journal-title":"Psychiatr Genet"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/ajmg.b.20169","article-title":"Weight gain associated with the \u2212759C\/T polymorphism of the 5HT2C receptor and olanzapine","volume":"134B","author":"Ellingrod","year":"2005","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.10.010_bib35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/YIC.0b013e328314e1f3","article-title":"Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies","volume":"23","author":"Emsley","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.10.010_bib36","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pharmthera.2009.10.010_bib37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1471-2202-7-69","article-title":"Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs","volume":"7","author":"Ferno","year":"2006","journal-title":"BMC Neurosci"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.10.010_bib38","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/0361-9230(85)90006-1","article-title":"Analysis of dopamine D1 and D2 receptor involvement in d- and l-amphetamine-induced anorexia in rats","volume":"15","author":"Gilbert","year":"1985","journal-title":"Brain Res Bull"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0014-2999(85)90578-3","article-title":"Postsynaptic alpha 2-noradrenergic receptors mediate feeding induced by paraventricular nucleus injection of norepinephrine and clonidine","volume":"115","author":"Goldman","year":"1985","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.10.010_bib40","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1038\/sj.npp.1300291","article-title":"H(1)-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Goudie","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.10.010_bib41","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1365-2265.1998.00403.x","article-title":"Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels","volume":"48","author":"Greenman","year":"1998","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.10.010_bib42","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.psyneuen.2008.01.018","article-title":"Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression","volume":"33","author":"Han","year":"2008","journal-title":"Psychoneuroendocrinology"},{"issue":"2\u20133","key":"10.1016\/j.pharmthera.2009.10.010_bib43","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00213-004-2019-z","article-title":"Agonist diversity in 5-HT(2C) receptor-mediated weight control in rats","volume":"178","author":"Hayashi","year":"2005","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib44","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S0022-3565(24)38891-3","article-title":"Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors","volume":"295","author":"Herrick-Davis","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pharmthera.2009.10.010_bib45","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/ar.1090780203","article-title":"Hypothalamic lesions and adiposity in the rat","volume":"78","author":"Hetherington","year":"1940","journal-title":"Anat Rec"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.brainres.2007.02.038","article-title":"5-HT2C receptor gene polymorphisms associated with antipsychotic drug action alter promoter activity","volume":"1149","author":"Hill","year":"2007","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib47","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/00041444-200209000-00009","article-title":"Genetic variant of the histamine-1 receptor (glu349asp) and body weight change during clozapine treatment","volume":"12","author":"Hong","year":"2002","journal-title":"Psychiatr Genet"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib48","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0091-3057(95)00315-N","article-title":"Raclopride reduces sucrose preference in rats","volume":"50","author":"Hsiao","year":"1995","journal-title":"Pharmacol Biochem Behav"},{"issue":"8","key":"10.1016\/j.pharmthera.2009.10.010_bib49","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1038\/sj.bjp.0701311","article-title":"Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat","volume":"121","author":"Jackson","year":"1997","journal-title":"Br J Pharmacol"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2009.10.010_bib50","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.schres.2007.11.026","article-title":"Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin","volume":"100","author":"Jin","year":"2008","journal-title":"Schizophr Res"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.10.010_bib51","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/diabetes.54.5.1552","article-title":"Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perfused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia","volume":"54","author":"Johnson","year":"2005","journal-title":"Diabetes"},{"issue":"9618","key":"10.1016\/j.pharmthera.2009.10.010_bib52","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(08)60486-9","article-title":"Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial","volume":"371","author":"Kahn","year":"2008","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.10.010_bib53","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.10.010_bib54","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/0269881106061199","article-title":"Clozapine, but not haloperidol, increases neuropeptide Y neuronal expression in the rat hypothalamus","volume":"20","author":"Kirk","year":"2006","journal-title":"J Psychopharmacol (Oxford, England)"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib55","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00213-009-1639-8","article-title":"Olanzapine-induced weight gain in the rat: Role of 5-HT2C and histamine H1 receptors","volume":"207","author":"Kirk","year":"2009","journal-title":"Psychopharmacology"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2009.10.010_bib56","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ejphar.2004.10.015","article-title":"Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat","volume":"505","author":"Kirk","year":"2004","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib57","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib58","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/sj.mp.4002133","article-title":"Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects?","volume":"14","author":"Le Hellard","year":"2009","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pharmthera.2009.10.010_bib59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.autneu.2006.02.027","article-title":"Brain-derived neurotrophic factor (BDNF) and food intake regulation: a minireview","volume":"126\u2013127","author":"Lebrun","year":"2006","journal-title":"Auton Neuroscie"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2009.10.010_bib60","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0006-8993(98)00186-3","article-title":"Effects of intracerebroventricularly infused histamine and selective H1, H2 and H3 agonists on food and water intake and urine flow in Wistar rats","volume":"793","author":"Lecklin","year":"1998","journal-title":"Brain Res"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.10.010_bib61","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0091-3057(84)80022-2","article-title":"Chronic norepinephrine injection into the hypothalamic paraventricular nucleus produces hyperphagia and increased body weight in the rat","volume":"21","author":"Leibowitz","year":"1984","journal-title":"Pharmacol Biochem Behav"},{"issue":"12","key":"10.1016\/j.pharmthera.2009.10.010_bib62","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"issue":"Pt 5","key":"10.1016\/j.pharmthera.2009.10.010_bib63","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1017\/S0003480000008277","article-title":"Association of the G-2548A polymorphism in the 5\u2032 region of the LEP gene with overweight","volume":"64","author":"Mammes","year":"2000","journal-title":"Ann Hum Genet"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.10.010_bib64","first-page":"435","article-title":"Adjunctive aripiprazole decreased metabolic side effects of clozapine treatment","volume":"29","author":"Masopust","year":"2008","journal-title":"Neuro Endocrinol Lett"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.10.010_bib65","doi-asserted-by":"crossref","first-page":"368","DOI":"10.2133\/dmpk.20.368","article-title":"Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus","volume":"20","author":"Matsui-Sakata","year":"2005","journal-title":"Drug Metab Pharmacokinet"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib66","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0006-8993(84)91013-8","article-title":"Clonidine-induced feeding: analysis of central sites of action and fiber projections mediating this response","volume":"309","author":"McCabe","year":"1984","journal-title":"Brain Res"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.10.010_bib67","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1373\/clinchem.2004.032482","article-title":"Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin","volume":"50","author":"Meier","year":"2004","journal-title":"Clin Chem"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib68","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ajmg.b.30115","article-title":"Clozapine-induced weight gain associated with the 5HT2C receptor \u2212759C\/T polymorphism","volume":"133B","author":"Miller","year":"2005","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.10.010_bib69","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1176\/appi.ajp.164.4.630","article-title":"Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia","volume":"164","author":"Mizrahi","year":"2007","journal-title":"Am J Psychiatry"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.10.010_bib70","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1097\/JCP.0b013e3180a76dc0","article-title":"The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia","volume":"27","author":"Mulder","year":"2007","journal-title":"J Clin Psychopharmacol"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.10.010_bib71","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.neulet.2004.12.037","article-title":"The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia","volume":"379","author":"Muller","year":"2005","journal-title":"Neurosci Lett"},{"issue":"7","key":"10.1016\/j.pharmthera.2009.10.010_bib72","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.psyneuen.2007.05.007","article-title":"Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats","volume":"32","author":"Murashita","year":"2007","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib73","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.mp.4002066","article-title":"Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles","volume":"13","author":"Nasrallah","year":"2008","journal-title":"Mol Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.pharmthera.2009.10.010_bib74","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"issue":"7 Suppl","key":"10.1016\/j.pharmthera.2009.10.010_bib75","first-page":"S170","article-title":"Metabolic syndrome and mental illness","volume":"13","author":"Newcomer","year":"2007","journal-title":"Am J Manag Care"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.10.010_bib76","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1001\/archpsyc.59.4.337","article-title":"Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia","volume":"59","author":"Newcomer","year":"2002","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.10.010_bib77","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/archpsyc.64.2.242","article-title":"Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's general practice research database","volume":"64","author":"Osborn","year":"2007","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib78","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.neulet.2006.11.018","article-title":"Risperidone reduces mRNA expression levels of sulfonylurea receptor 1 and TASK1 in PC12 cells","volume":"412","author":"Ota","year":"2007","journal-title":"Neurosci Lett"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.10.010_bib79","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/0091-3057(88)90120-7","article-title":"Sulpiride injections in the lateral hypothalamus induce feeding and drinking in rats","volume":"30","author":"Parada","year":"1988","journal-title":"Pharmacol Biochem Behav"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib80","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0091-3057(89)90427-9","article-title":"Mechanism of the body weight increase induced by systemic sulpiride","volume":"33","author":"Parada","year":"1989","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.10.010_bib81","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/ajmg.b.30311","article-title":"Weight gain associated with the alpha2a-adrenergic receptor \u22121,291 C\/G polymorphism and olanzapine treatment","volume":"141B","author":"Park","year":"2006","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib82","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0b013e318172b8e6","article-title":"Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1year of treatment","volume":"28","author":"Perez-Iglesias","year":"2008","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.10.010_bib83","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","article-title":"Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial","volume":"68","author":"Potkin","year":"2007","journal-title":"J Clin Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2009.10.010_bib84","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11010-006-9160-4","article-title":"SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects?","volume":"289","author":"Raeder","year":"2006","journal-title":"Mol Cell Biochem"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib85","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1177\/026988110401800303","article-title":"Receptor mechanisms in the treatment of schizophrenia","volume":"18","author":"Reynolds","year":"2004","journal-title":"J Psychopharmacol"},{"issue":"4 SUPPL.","key":"10.1016\/j.pharmthera.2009.10.010_bib86","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1359786806066040","article-title":"The S-HT2C receptor and antipsychotic-induced weight gain\u2014mechanisms and genetics","volume":"20","author":"Reynolds","year":"2006","journal-title":"J Psychopharmacol"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.10.010_bib87","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1176\/appi.ajp.160.4.677","article-title":"Polymorphism of the promoter region of the serotonin 5-HT2C receptor gene and clozapine-induced weight gain","volume":"160","author":"Reynolds","year":"2003","journal-title":"Am J Psychiatry"},{"issue":"9323","key":"10.1016\/j.pharmthera.2009.10.010_bib88","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/S0140-6736(02)08913-4","article-title":"Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism","volume":"359","author":"Reynolds","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib89","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0024-3205(00)00911-5","article-title":"Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds","volume":"68","author":"Richelson","year":"2000","journal-title":"Life Sci"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2009.10.010_bib90","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0006-8993(88)91423-0","article-title":"Blockade of the histamine H1-receptor in the rat ventromedial hypothalamus and feeding elicitation","volume":"441","author":"Sakata","year":"1988","journal-title":"Brain Res"},{"issue":"1\u20132","key":"10.1016\/j.pharmthera.2009.10.010_bib91","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology"},{"issue":"6778","key":"10.1016\/j.pharmthera.2009.10.010_bib92","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/35007534","article-title":"Central nervous system control of food intake","volume":"404","author":"Schwartz","year":"2000","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib93","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature","volume":"23","author":"Shahid","year":"2009","journal-title":"J Psychopharmacol (Oxford, England)"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.10.010_bib94","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1358\/mf.2005.27.5.908643","article-title":"Research on adverse drug events. I. muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes","volume":"27","author":"Silvestre","year":"2005","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib95","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.tpj.6500474","article-title":"Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia","volume":"8","author":"Smith","year":"2008","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.10.010_bib96","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1177\/0269881107081519","article-title":"Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats","volume":"22","author":"Snigdha","year":"2008","journal-title":"J Psychopharmacol (Oxford, England)"},{"issue":"6659","key":"10.1016\/j.pharmthera.2009.10.010_bib97","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/37379","article-title":"Leptin inhibits hypothalamic neurons by activation of ATP-sensitive potassium channels","volume":"390","author":"Spanswick","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2009.10.010_bib98","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.162.2.249","article-title":"The distribution of adipose tissue in female in-patients receiving psychotropic drugs","volume":"162","author":"Stedman","year":"1993","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pharmthera.2009.10.010_bib99","article-title":"Asenapine induces differential regional effects on serotonin receptor subtypes","author":"Tarazi","year":"2008","journal-title":"J Psychopharmacol Oxford (England)"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib100","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00213-002-1016-3","article-title":"Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions","volume":"161","author":"Tarazi","year":"2002","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.10.010_bib101","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-0447.2000.101006416.x","article-title":"Atypical antipsychotics and weight gain\u2014a systematic review","volume":"101","author":"Taylor","year":"2000","journal-title":"Acta Psychiatr Scand"},{"issue":"6522","key":"10.1016\/j.pharmthera.2009.10.010_bib102","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/374542a0","article-title":"Eating disorder and epilepsy in mice lacking 5-HT2c serotonin receptors","volume":"374","author":"Tecott","year":"1995","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.10.010_bib103","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/01213011-200504000-00002","article-title":"Polymorphisms of the 5-HT2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis","volume":"15","author":"Templeman","year":"2005","journal-title":"Pharmacogenetics Genomics"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.10.010_bib104","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/sj.tpj.6500418","article-title":"No evidence for binding of clozapine, olanzapine and\/or haloperidol to selected receptors involved in body weight regulation","volume":"7","author":"Theisen","year":"2007","journal-title":"Pharmacogenomics J"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.10.010_bib105","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/10398560701636906","article-title":"Body mass index as a screening test for metabolic syndrome in schizophrenia and schizoaffective disorders","volume":"15","author":"Tirupati","year":"2007","journal-title":"Australas Psychiatry"},{"issue":"10","key":"10.1016\/j.pharmthera.2009.10.010_bib106","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.fpc.0000175600.26893.fa","article-title":"C825T polymorphism in the human G protein beta3 subunit gene is associated with long-term clozapine treatment-induced body weight change in the Chinese population","volume":"15","author":"Wang","year":"2005","journal-title":"Pharmacogenetics Genomics"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.10.010_bib107","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.2337\/diacare.24.9.1590","article-title":"Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men","volume":"24","author":"Wannamethee","year":"2001","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pharmthera.2009.10.010_bib108","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0091-3057(92)90452-L","article-title":"Reversal of cirazoline- and phenylpropanolamine-induced anorexia by the alpha 1-receptor antagonist prazosin","volume":"42","author":"Wellman","year":"1992","journal-title":"Pharmacol Biochem Behav"},{"issue":"4\u20135","key":"10.1016\/j.pharmthera.2009.10.010_bib109","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0031-9384(01)00612-6","article-title":"The hypothalamus and the control of energy homeostasis: different circuits, different purposes","volume":"74","author":"Williams","year":"2001","journal-title":"Physiol Behav"},{"issue":"2","key":"10.1016\/j.pharmthera.2009.10.010_bib110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0028-3908(01)00056-9","article-title":"A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze","volume":"41","author":"Woolley","year":"2001","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib111","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0920-9964(96)82950-1","article-title":"Autoimmune diseases in the pedigrees of schizophrenic and control subjects","volume":"20","author":"Wright","year":"1996","journal-title":"Schizophr Res"},{"issue":"6","key":"10.1016\/j.pharmthera.2009.10.010_bib112","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1192\/bjp.bp.107.041723","article-title":"Influence of 5-HT2C receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia","volume":"192","author":"Yevtushenko","year":"2008","journal-title":"Br J Psychiatry"},{"issue":"4","key":"10.1016\/j.pharmthera.2009.10.010_bib113","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.bcp.2005.11.007","article-title":"Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms","volume":"71","author":"Zhang","year":"2006","journal-title":"Biochem Pharmacol"},{"issue":"9","key":"10.1016\/j.pharmthera.2009.10.010_bib114","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/sj.npp.1301619","article-title":"BDNF levels and genotype are associated with antipsychotic-induced weight gain in patients with chronic schizophrenia","volume":"33","author":"Zhang","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2009.10.010_bib115","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1192\/bjp.184.1.58","article-title":"Effects of antipsychotics on fat deposition and changes in leptin and insulin levels. magnetic resonance imaging study of previously untreated people with schizophrenia","volume":"184","author":"Zhang","year":"2004","journal-title":"Br J Psychiatry"},{"issue":"24","key":"10.1016\/j.pharmthera.2009.10.010_bib116","first-page":"2119","article-title":"Association of \u22122548G\/A functional polymorphism in the promoter region of leptin gene with antipsychotic agent-induced weight gain","volume":"83","author":"Zhang","year":"2003","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"3","key":"10.1016\/j.pharmthera.2009.10.010_bib117","first-page":"235","article-title":"No association of antipsychotic agent-induced weight gain with a DA receptor gene polymorphism and therapeutic response","volume":"24","author":"Zhang","year":"2003","journal-title":"Acta Pharmacologica Sinica"},{"issue":"5","key":"10.1016\/j.pharmthera.2009.10.010_bib118","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.cmet.2007.10.008","article-title":"Serotonin 2C receptor agonists improve type 2 diabetes via melanocortin-4 receptor signaling pathways","volume":"6","author":"Zhou","year":"2007","journal-title":"Cell Metabolism"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725809002149?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725809002149?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T08:54:21Z","timestamp":1739436861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725809002149"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":118,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0163725809002149"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2009.10.010","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}